{"nctId":"NCT03677934","briefTitle":"A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration","startDateStruct":{"date":"2018-09-12","type":"ACTUAL"},"conditions":["Neovascular Age-Related Macular Degeneration"],"count":415,"armGroups":[{"label":"PDS Implant Arm","type":"EXPERIMENTAL","interventionNames":["Drug: PDS Implant filled with 100 mg/mL Ranibizumab"]},{"label":"Intravitreal Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Intravitreal Injections of 10 mg/mL Ranibizumab"]}],"interventions":[{"name":"PDS Implant filled with 100 mg/mL Ranibizumab","otherNames":[]},{"name":"Intravitreal Injections of 10 mg/mL Ranibizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥50 years, at time of signing Informed Consent Form\n* Initial diagnosis of exudative neovascular age-related macular degeneration (nAMD) within 9 months prior to the screening visit\n* Previous treatment with at least three anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit\n* Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis\n* Best-corrected visual acuity (BCVA) of 34 letters or better\n\nExclusion Criteria:\n\n* Subfoveal fibrosis or subfoveal atrophy in study eye\n* Subretinal hemorrhage that involves the center of the fovea in study eye\n* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye\n* Prior treatment with Visudyne®, external-beam radiation therapy, or transpupillary thermotherapy in study eye\n* Previous intraocular device implantation in study eye\n* Previous laser (any type) used for AMD treatment in study eye\n* Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit in either eye\n* Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the randomization visit, other than ranibizumab in either eye\n* CNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia in either eye\n* Uncontrolled blood pressure\n* History of stroke within the last 3 months prior to informed consent\n* Uncontrolled atrial fibrillation within 3 months of informed consent\n* History of myocardial infarction within the last 3 months prior to informed consent\n* History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the Implant and that might affect interpretation of the results of the study or renders the participant at high risk of treatment complications in the opinion of the investigator\n* Current systemic treatment for a confirmed active systemic infection\n* Chronic use of oral corticosteroids\n* Active cancer within 12 months of randomization\n* Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month preceding the informed consent (excluding vitamins and minerals)","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the ETDRS Visual Acuity Chart at a Starting Distance of 4 Meters","description":"The primary efficacy endpoint is the change in BCVA score from baseline averaged over Weeks 36 and 40 with BCVA assessed using the ETDRS chart at a starting distance of 4 meters. ETDRS = Early Treatment Diabetic Retinopathy Study.\n\nThe primary objective is to determine the NI and equivalence between the two treatment groups, as measured by the primary efficacy endpoint with a NI margin of 4.5 letters and equivalence margins of ± 4.5 letters.\n\nA vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.","paramType":"MEAN","dispersionType":"95.03% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA Score Averaged Over Week 60 and Week 64","description":null,"paramType":"MEAN","dispersionType":"95.03% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BCVA Score Over Time","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"0.47"},{"groupId":"OG001","value":"-0.4","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.41"},{"groupId":"OG001","value":"0.1","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.39"},{"groupId":"OG001","value":"0.6","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.41"},{"groupId":"OG001","value":"0.2","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.42"},{"groupId":"OG001","value":"0.1","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.47"},{"groupId":"OG001","value":"0.8","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.47"},{"groupId":"OG001","value":"0.5","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.49"},{"groupId":"OG001","value":"0.9","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.47"},{"groupId":"OG001","value":"0.3","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.51"},{"groupId":"OG001","value":"0.7","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.53"},{"groupId":"OG001","value":"0.6","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.53"},{"groupId":"OG001","value":"-0.2","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.54"},{"groupId":"OG001","value":"-0.8","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.56"},{"groupId":"OG001","value":"-0.5","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.58"},{"groupId":"OG001","value":"-0.8","spread":"0.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.59"},{"groupId":"OG001","value":"-0.7","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.64"},{"groupId":"OG001","value":"-0.3","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.64"},{"groupId":"OG001","value":"0.1","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.68"},{"groupId":"OG001","value":"0.2","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.64"},{"groupId":"OG001","value":"-0.2","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.62"},{"groupId":"OG001","value":"0.3","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.62"},{"groupId":"OG001","value":"0.0","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.63"},{"groupId":"OG001","value":"-1.0","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.68"},{"groupId":"OG001","value":"-1.3","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse at the Average Over Week 36 and Week 40","description":null,"paramType":"NUMBER","dispersionType":"95.03% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better at the Average Over Week 36 and Week 40","description":null,"paramType":"NUMBER","dispersionType":"95.03% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":null},{"groupId":"OG001","value":"82.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"78.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Lose <10 or <5 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week 40","description":null,"paramType":"NUMBER","dispersionType":"95.03% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null},{"groupId":"OG001","value":"95.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Lose <10 or <5 Letters in BCVA Score From Baseline Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.1","spread":null},{"groupId":"OG001","value":"73.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gain ≥0 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week 40","description":null,"paramType":"NUMBER","dispersionType":"95.03% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Gain ≥0 Letters in BCVA Score From Baseline Over Time","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Center Point Thickness (CPT) at Week 36","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176.9","spread":"3.48"},{"groupId":"OG001","value":"177.4","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"2.91"},{"groupId":"OG001","value":"2.6","spread":"3.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CPT Over Time","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176.9","spread":"3.48"},{"groupId":"OG001","value":"177.4","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.05"},{"groupId":"OG001","value":"2.1","spread":"2.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.17"},{"groupId":"OG001","value":"3.0","spread":"2.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"2.87"},{"groupId":"OG001","value":"0.3","spread":"3.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"3.45"},{"groupId":"OG001","value":"7.3","spread":"4.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"2.7"},{"groupId":"OG001","value":"1.3","spread":"3.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"2.5"},{"groupId":"OG001","value":"-0.8","spread":"3.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.5"},{"groupId":"OG001","value":"1.6","spread":"3.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"2.69"},{"groupId":"OG001","value":"2.3","spread":"3.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"2.91"},{"groupId":"OG001","value":"2.7","spread":"3.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"3.37"},{"groupId":"OG001","value":"5.1","spread":"4.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"3.13"},{"groupId":"OG001","value":"3.4","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"3.55"},{"groupId":"OG001","value":"6.4","spread":"4.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"3.43"},{"groupId":"OG001","value":"6.6","spread":"4.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"3.36"},{"groupId":"OG001","value":"3.3","spread":"4.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"3.39"},{"groupId":"OG001","value":"2.5","spread":"4.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"3.54"},{"groupId":"OG001","value":"3.6","spread":"4.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"3.48"},{"groupId":"OG001","value":"2.1","spread":"4.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"3.35"},{"groupId":"OG001","value":"0.9","spread":"4.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"3.61"},{"groupId":"OG001","value":"0.1","spread":"4.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"3.56"},{"groupId":"OG001","value":"-2.7","spread":"4.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"3.87"},{"groupId":"OG001","value":"-2.0","spread":"4.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"3.88"},{"groupId":"OG001","value":"-0.6","spread":"4.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"3.57"},{"groupId":"OG001","value":"-1.3","spread":"4.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"3.64"},{"groupId":"OG001","value":"-1.3","spread":"4.48"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in the PDS Implant Arm Who Undergo Supplemental Treatment With Intravitreal Ranibizumab 0.5 mg Before the First, Second, Third, and Fourth Fixed Refill-Exchange Intervals","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"242","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"213","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in the PDS Implant Arm Who Undergo a Supplemental Treatment That Requires Subsequent Additional Supplemental Treatments During the Study","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Ocular and Systemic (Non-Ocular) AEs","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events of Special Interest","description":"Percentage of Participants with Adverse Events of Special Interest","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Serum Ranibizumab Concentrations at Specified Timepoints","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.125","spread":"115"},{"groupId":"OG001","value":"0.117","spread":"78.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.397","spread":"71.1"},{"groupId":"OG001","value":"0.0592","spread":"180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.564","spread":"40.7"},{"groupId":"OG001","value":"0.0581","spread":"178"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.289","spread":"90.6"},{"groupId":"OG001","value":"0.0594","spread":"146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.499","spread":"41.7"},{"groupId":"OG001","value":"0.0531","spread":"123"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.257","spread":"73.7"},{"groupId":"OG001","value":"0.0376","spread":"152"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.291","spread":"247"},{"groupId":"OG001","value":"0.0500","spread":"127"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.191","spread":"154"},{"groupId":"OG001","value":"0.0680","spread":"157"}]}]}]},{"type":"SECONDARY","title":"Estimated PK Parameter Values AUC0-6M","description":"AUC0-6M = Area Under the Concentration-Time Curve From 0 to 6 Months","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.42","spread":"21.11"}]}]}]},{"type":"SECONDARY","title":"Estimated PK Parameter Value t1/2 After PDS Implant Insertion","description":"Apparent terminal half-life","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"442.29","spread":"276.92"}]}]}]},{"type":"SECONDARY","title":"Estimated PK Parameter Value Cmin","description":"Cmin = Minimum Serum Concentration","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Estimated PK Parameter Value Cmax","description":"Cmax = Maximum Serum Concentration","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Baseline Prevalence and Incidence of Treatment-Emergent ADA","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"238","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":39,"n":167},"commonTop":["Conjunctival haemorrhage","Conjunctival hyperaemia","Iritis","Neovascular age-related macular degeneration","Eye pain"]}}}